ADIPOQ and non-small cell lung carcinoma: Perturbations in the Acrp30 system, as we have demonstrated in lung cancer patients, may result in the modulation of anti-proliferative and anti-inflammatory effects induced by Acrp30, which might offer novel therapeutic options for patients with NSCLC.